Division of Nephrology and Hypertension, College of Medicine, Mayo Clinic, Rochester, MN, USA.
Am J Kidney Dis. 2013 Aug;62(2):201-13. doi: 10.1053/j.ajkd.2013.03.018. Epub 2013 May 16.
In response to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for blood pressure management in patients with chronic kidney disease not on dialysis, the National Kidney Foundation organized a group of US experts in hypertension and transplant nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The overriding message was the dearth of clinical trial evidence to provide strong evidence-based recommendations. For patients with CKD with normal to mildly increased albuminuria, goal blood pressure has been relaxed to ≤140/90 mm Hg for both diabetic and nondiabetic patients. In contrast, KDIGO continues to recommend goal blood pressure ≤130/80 mm Hg for patients with chronic kidney disease with moderately or severely increased albuminuria and for all renal transplant recipients regardless of the presence of proteinuria, without supporting data. The expert panel thought the KDIGO recommendations were generally reasonable but lacking in sufficient evidence support and that additional studies are greatly needed.
针对 2012 年 KDIGO(肾脏疾病:改善全球预后)关于非透析慢性肾脏病患者血压管理的指南,美国国家肾脏基金会组织了一组高血压和移植肾病学专家,对这些建议进行了审查,并就其与当前美国临床实践和关注点的相关性发表了评论。主要信息是缺乏临床试验证据来提供强有力的基于证据的建议。对于白蛋白尿正常或轻度增加的 CKD 患者,糖尿病和非糖尿病患者的目标血压已放宽至≤140/90mmHg。相比之下,KDIGO 继续建议中度或重度白蛋白尿增加的慢性肾脏病患者和所有肾移植受者的目标血压≤130/80mmHg,无论蛋白尿是否存在,而没有支持数据。专家组认为,KDIGO 的建议总体上是合理的,但缺乏足够的证据支持,需要开展更多的研究。